Zhongnan Hospital

This phase II trial is testing a combination of two drugs, Utidelone and Toripalimab, in people with recurrent or metastatic cervical cancer that has not responded to standard treatments. All 32 participants will receive the same treatment, and doctors will monitor tumor shrinkag…

This phase II trial tests a chemotherapy regimen called FULIRI, combined with either bevacizumab or cetuximab, as a first treatment for colorectal cancer that has spread to the liver. The goal is to shrink the liver tumors enough so they can be surgically removed. The study will …

This study tests whether adding an immunotherapy drug (QL1706) to standard chemoradiation helps shrink advanced rectal cancer before surgery. About 108 adults with stage 2 or 3 rectal cancer will be randomly assigned to receive either chemoradiation plus immunotherapy or chemorad…

This study is testing a new imaging agent called 68Ga-SFB6-ZN01 that attaches to a protein found on many cancer cells. About 98 adults with confirmed or suspected cancer will get one injection and one PET/CT scan. The goal is to see if the agent is safe and can accurately detect …

This study will test a new imaging agent called 68Ga-B6FA-01, which targets two different markers on cancer cells and their surroundings. The goal is to see if this probe can improve PET/CT scans for diagnosing and staging solid tumors. About 100 adults with newly diagnosed or re…

This study tests a non-invasive device called Temporal Interference Stimulation (TIS) to see if it can improve movement in people with Parkinson's disease. The device uses electrical fields to stimulate deep brain areas without surgery. Twenty-four adults with mild to moderate Pa…